{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T21:09:35Z","timestamp":1792271375453,"version":"4.4.0"},"reference-count":76,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,3,14]],"date-time":"2025-03-14T00:00:00Z","timestamp":1741910400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,3,14]],"date-time":"2025-03-14T00:00:00Z","timestamp":1741910400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AAPS J"],"DOI":"10.1208\/s12248-025-01050-9","type":"journal-article","created":{"date-parts":[[2025,3,14]],"date-time":"2025-03-14T16:44:34Z","timestamp":1741970674000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Therapeutic Drug Monitoring of Biologics: Current Practice, Challenges and Opportunities \u2013 a Workshop Report"],"prefix":"10.1208","volume":"27","author":[{"given":"Sophie","family":"Shubow","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Gunsior","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Rosenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yow-Ming","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tara","family":"Altepeter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daphne","family":"Guinn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohsen","family":"Rajabiabhari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Kotarek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diane R.","family":"Mould","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Honghui","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam S.","family":"Cheifetz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Garces","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Chevalier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean","family":"Gavan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark R.","family":"Trusheim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theo","family":"Rispens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kurtis","family":"Bray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6699-8473","authenticated-orcid":false,"given":"Michael A.","family":"Partridge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,14]]},"reference":[{"issue":"4","key":"1050_CR1","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1038\/clpt.2012.113","volume":"92","author":"LJ Lesko","year":"2012","unstructured":"Lesko LJ, Schmidt S. Individualization of Drug Therapy: History, Present State, and Opportunities for the Future. Clin Pharm Therap. 2012;92(4):458\u201366. https:\/\/doi.org\/10.1038\/clpt.2012.113.","journal-title":"Clin Pharm Therap"},{"issue":"6","key":"1050_CR2","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1136\/annrheumdis-2013-203296","volume":"73","author":"S Garc\u00eas","year":"2014","unstructured":"Garc\u00eas S, Antunes M, Benito-Garcia E, da Silva JC, Aarden L, Demengeot J. A preliminary algorithm introducing immunogenicity assessment in the management of patients with RA receiving tumour necrosis factor inhibitor therapies. Ann Rheum Dis. 2014;73(6):1138\u201343. https:\/\/doi.org\/10.1136\/annrheumdis-2013-203296.","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"1050_CR3","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1177\/1756283x16643242","volume":"9","author":"MA Sofia","year":"2016","unstructured":"Sofia MA, Rubin DT. Current approaches for optimizing the benefit of biologic therapy in ulcerative colitis. Therap Adv Gastroenterol. 2016;9(4):548\u201359. https:\/\/doi.org\/10.1177\/1756283x16643242.","journal-title":"Therap Adv Gastroenterol"},{"issue":"14","key":"1050_CR4","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1001\/jama.2011.406","volume":"305","author":"GM Bartelds","year":"2011","unstructured":"Bartelds GM, Krieckaert CL, Nurmohamed MT, et al. Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up. JAMA. 2011;305(14):1460\u20138. https:\/\/doi.org\/10.1001\/jama.2011.406.","journal-title":"JAMA"},{"issue":"10","key":"1050_CR5","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1016\/j.cgh.2017.03.031","volume":"15","author":"K Papamichael","year":"2017","unstructured":"Papamichael K, Chachu KA, Vajravelu RK, et al. Improved Long-term Outcomes of Patients With Inflammatory Bowel Disease Receiving Proactive Compared With Reactive Monitoring of Serum Concentrations of Infliximab. Clin Gastroenterol Hepatol. 2017;15(10):1580-1588.e3. https:\/\/doi.org\/10.1016\/j.cgh.2017.03.031.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"1050_CR6","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1002\/cpt.1933","volume":"109","author":"K Maxfield","year":"2021","unstructured":"Maxfield K, Milligan L, Wang L, et al. Proceedings of a Workshop: Precision Dosing: Defining the Need and Approaches to Deliver Individualized Drug Dosing in the Real-World Setting. Clin Pharmacol Ther. 2021;109(1):25\u20138. https:\/\/doi.org\/10.1002\/cpt.1933.","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"1050_CR7","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1097\/mib.0000000000000202","volume":"21","author":"K Papamichael","year":"2015","unstructured":"Papamichael K, Gils A, Rutgeerts P, et al. Role for therapeutic drug monitoring during induction therapy with TNF antagonists in IBD: evolution in the definition and management of primary nonresponse. Inflamm Bowel Dis. 2015;21(1):182\u201397. https:\/\/doi.org\/10.1097\/mib.0000000000000202.","journal-title":"Inflamm Bowel Dis."},{"issue":"6","key":"1050_CR8","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1016\/j.clinthera.2016.03.018","volume":"38","author":"M Miligkos","year":"2016","unstructured":"Miligkos M, Papamichael K, VandeCasteele N, et al. Efficacy and safety profile of anti-tumor necrosis factor-\u03b1 versus anti-integrin agents for the treatment of crohn\u2019s disease: a network meta-analysis of indirect comparisons. Clin Ther. 2016;38(6):1342-1358.e6. https:\/\/doi.org\/10.1016\/j.clinthera.2016.03.018.","journal-title":"Clin Ther"},{"issue":"5","key":"1050_CR9","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/s2468-1253(19)30012-3","volume":"4","author":"NA Kennedy","year":"2019","unstructured":"Kennedy NA, Heap GA, Green HD, et al. Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn\u2019s disease: a prospective, multicentre, cohort study. Lancet Gastroenterol Hepatol. 2019;4(5):341\u201353. https:\/\/doi.org\/10.1016\/s2468-1253(19)30012-3.","journal-title":"Lancet Gastroenterol Hepatol."},{"key":"1050_CR10","doi-asserted-by":"publisher","unstructured":"Deyhim T, Cheifetz AS, Papamichael K. Drug Clearance in patients with inflammatory bowel disease treated with biologics. J Clin Med. 2023;12(22). https:\/\/doi.org\/10.3390\/jcm12227132.","DOI":"10.3390\/jcm12227132"},{"issue":"4","key":"1050_CR11","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1002\/cpt.334","volume":"99","author":"DR Mould","year":"2016","unstructured":"Mould DR, D\u2019Haens G, Upton RN. Clinical decision support tools: the evolution of a revolution. Clin Pharmacol Ther. 2016;99(4):405\u201318. https:\/\/doi.org\/10.1002\/cpt.334.","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"1050_CR12","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1080\/00365521.2020.1856405","volume":"56","author":"AS Strik","year":"2021","unstructured":"Strik AS, L\u00f6wenberg M, Mould DR, et al. Efficacy of dashboard driven dosing of infliximab in inflammatory bowel disease patients; a randomized controlled trial. Scand J Gastroenterol. 2021;56(2):145\u201354. https:\/\/doi.org\/10.1080\/00365521.2020.1856405.","journal-title":"Scand J Gastroenterol"},{"issue":"9","key":"1050_CR13","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1093\/ibd\/izab285","volume":"28","author":"MC Dubinsky","year":"2022","unstructured":"Dubinsky MC, Mendiolaza ML, Phan BL, Moran HR, Tse SS, Mould DR. Dashboard-Driven Accelerated Infliximab Induction Dosing Increases Infliximab Durability and Reduces Immunogenicity. Inflamm Bowel Dis. 2022;28(9):1375\u201385. https:\/\/doi.org\/10.1093\/ibd\/izab285.","journal-title":"Inflamm Bowel Dis"},{"issue":"4","key":"1050_CR14","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1002\/jcph.2189","volume":"63","author":"DC Desai","year":"2023","unstructured":"Desai DC, Dherai AJ, Strik A, Mould DR. Personalized dosing of infliximab in patients with inflammatory bowel disease using a bayesian approach: a next step in therapeutic drug monitoring. J Clin Pharmacol. 2023;63(4):480\u20139. https:\/\/doi.org\/10.1002\/jcph.2189.","journal-title":"J Clin Pharmacol."},{"issue":"6","key":"1050_CR15","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1053\/j.gastro.2014.08.035","volume":"147","author":"OJ Adedokun","year":"2014","unstructured":"Adedokun OJ, Sandborn WJ, Feagan BG, et al. Association between serum concentration of infliximab and efficacy in adult patients with ulcerative colitis. Gastroenterology. 2014;147(6):1296-1307.e5. https:\/\/doi.org\/10.1053\/j.gastro.2014.08.035.","journal-title":"Gastroenterology"},{"issue":"23","key":"1050_CR16","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1001\/jama.2021.21316","volume":"326","author":"SW Syversen","year":"2021","unstructured":"Syversen SW, J\u00f8rgensen KK, Goll GL, et al. Effect of therapeutic drug monitoring vs standard therapy during maintenance infliximab therapy on disease control in patients with immune-mediated inflammatory diseases: a randomized clinical trial. JAMA. 2021;326(23):2375\u201384. https:\/\/doi.org\/10.1001\/jama.2021.21316.","journal-title":"JAMA"},{"issue":"1","key":"1050_CR17","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1136\/gut.2009.183095","volume":"59","author":"CH Seow","year":"2010","unstructured":"Seow CH, Newman A, Irwin SP, Steinhart AH, Silverberg MS, Greenberg GR. Trough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis. Gut. 2010;59(1):49\u201354. https:\/\/doi.org\/10.1136\/gut.2009.183095.","journal-title":"Gut"},{"issue":"12","key":"1050_CR18","doi-asserted-by":"publisher","first-page":"2568","DOI":"10.1097\/MIB.0b013e3182a77b41","volume":"19","author":"S Paul","year":"2013","unstructured":"Paul S, Del Tedesco E, Marotte H, et al. Therapeutic drug monitoring of infliximab and mucosal healing in inflammatory bowel disease: a prospective study. Inflamm Bowel Dis. 2013;19(12):2568\u201376. https:\/\/doi.org\/10.1097\/MIB.0b013e3182a77b41.","journal-title":"Inflamm Bowel Dis"},{"issue":"10","key":"1050_CR19","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1016\/j.cgh.2006.06.025","volume":"4","author":"EA Maser","year":"2006","unstructured":"Maser EA, Villela R, Silverberg MS, Greenberg GR. Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn\u2019s disease. Clin Gastroenterol Hepatol. 2006;4(10):1248\u201354. https:\/\/doi.org\/10.1016\/j.cgh.2006.06.025.","journal-title":"Clin Gastroenterol Hepatol."},{"issue":"7","key":"1050_CR20","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1053\/j.gastro.2015.02.031","volume":"148","author":"N VandeCasteele","year":"2015","unstructured":"VandeCasteele N, Ferrante M, Van Assche G, et al. Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease. Gastroenterology. 2015;148(7):1320-9.e3. https:\/\/doi.org\/10.1053\/j.gastro.2015.02.031.","journal-title":"Gastroenterology"},{"issue":"12","key":"1050_CR21","doi-asserted-by":"publisher","first-page":"2187","DOI":"10.1111\/exd.14731","volume":"32","author":"L Mastorino","year":"2023","unstructured":"Mastorino L, Susca S, Cariti C, et al. \u201cSuperresponders\u201d at biologic treatment for psoriasis: a comparative study among IL17 and IL23 inhibitors. Exp Dermatol. 2023;32(12):2187\u20138. https:\/\/doi.org\/10.1111\/exd.14731.","journal-title":"Exp Dermatol"},{"issue":"5","key":"1050_CR22","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1016\/j.cgh.2023.10.029","volume":"22","author":"V Jairath","year":"2024","unstructured":"Jairath V, Yarur A, Osterman MT, et al. ENTERPRET: a randomized controlled trial of vedolizumab dose optimization in patients with ulcerative colitis who have early nonresponse. Clin Gastroenterol Hepatol. 2024;22(5):1077-1086.e13. https:\/\/doi.org\/10.1016\/j.cgh.2023.10.029.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"11","key":"1050_CR23","doi-asserted-by":"publisher","first-page":"1996","DOI":"10.1097\/mib.0000000000000156","volume":"20","author":"BP Vaughn","year":"2014","unstructured":"Vaughn BP, Martinez-Vazquez M, Patwardhan VR, Moss AC, Sandborn WJ, Cheifetz AS. Proactive therapeutic concentration monitoring of infliximab may improve outcomes for patients with inflammatory bowel disease: results from a pilot observational study. Inflamm Bowel Dis. 2014;20(11):1996\u20132003. https:\/\/doi.org\/10.1097\/mib.0000000000000156.","journal-title":"Inflamm Bowel Dis"},{"issue":"4","key":"1050_CR24","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1053\/j.gastro.2019.06.003","volume":"157","author":"A Assa","year":"2019","unstructured":"Assa A, Matar M, Turner D, et al. Proactive monitoring of adalimumab trough concentration associated with increased clinical remission in children with Crohn\u2019s disease compared with reactive monitoring. Gastroenterology. 2019;157(4):985-996.e2. https:\/\/doi.org\/10.1053\/j.gastro.2019.06.003.","journal-title":"Gastroenterology"},{"issue":"6","key":"1050_CR25","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1111\/bcp.14229","volume":"86","author":"JG S\u00e1nchez-Hern\u00e1ndez","year":"2020","unstructured":"S\u00e1nchez-Hern\u00e1ndez JG, Rebollo N, Martin-Suarez A, Calvo MV, Mu\u00f1oz F. A 3-year prospective study of a multidisciplinary early proactive therapeutic drug monitoring programme of infliximab treatments in inflammatory bowel disease. Br J Clin Pharmacol. 2020;86(6):1165\u201375. https:\/\/doi.org\/10.1111\/bcp.14229.","journal-title":"Br J Clin Pharmacol"},{"key":"1050_CR26","doi-asserted-by":"publisher","unstructured":"Syed N, Tolaymat M, Brown SA, Sivasailam B, Cross RK. Proactive Drug Monitoring Is Associated With Higher Persistence to Infliximab and Adalimumab Treatment and Lower Healthcare Utilization Compared With Reactive and Clinical Monitoring. Crohns Colitis 360. 2020;2(3):otaa050. https:\/\/doi.org\/10.1093\/crocol\/otaa050.","DOI":"10.1093\/crocol\/otaa050"},{"issue":"4","key":"1050_CR27","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1093\/ibd\/izaa102","volume":"27","author":"JL Lyles","year":"2021","unstructured":"Lyles JL, Mulgund AA, Bauman LE, et al. Effect of a practice-wide anti-TNF proactive therapeutic drug monitoring program on outcomes in pediatric patients with inflammatory bowel disease. Inflamm Bowel Dis. 2021;27(4):482\u201392. https:\/\/doi.org\/10.1093\/ibd\/izaa102.","journal-title":"Inflamm Bowel Dis"},{"issue":"4","key":"1050_CR28","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1097\/mpg.0000000000003389","volume":"74","author":"M Gasparetto","year":"2022","unstructured":"Gasparetto M, Burgess N, Naik S, et al. Advantages of proactive therapeutic drug monitoring in a prospective cohort of children with inflammatory bowel disease treated with anti-tumour necrosis factor. J Pediatr Gastroenterol Nutr. 2022;74(4):484\u20139. https:\/\/doi.org\/10.1097\/mpg.0000000000003389.","journal-title":"J Pediatr Gastroenterol Nutr."},{"key":"1050_CR29","doi-asserted-by":"publisher","unstructured":"Kang B, Moon JS, Lee YJ, et al. DOP83 Proactive dosing is superior to clinically based dosing in terms of endoscopic healing in paediatric patients with Crohn\u2019s disease receiving maintenance infliximab: A randomized controlled trial. J Crohn\u2019s and Colitis. 2023;17(Supplement_1):i159-i159. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjac190.0123.","DOI":"10.1093\/ecco-jcc\/jjac190.0123"},{"key":"1050_CR30","doi-asserted-by":"publisher","unstructured":"Fernandes SR, Bernardo S, Saraiva S, et al. Proactive infliximab monitoring improves the rates of transmural remission in crohn\u2019s disease: a propensity score-matched analysis. Inflamm Bowel Dis. 2023; https:\/\/doi.org\/10.1093\/ibd\/izad272.","DOI":"10.1093\/ibd\/izad272"},{"key":"1050_CR31","doi-asserted-by":"publisher","unstructured":"Porth R, Deyhim T, Geeganage G, et al. Proactive therapeutic drug monitoring of ustekinumab is associated with increased drug persistence in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2024;izae231. https:\/\/doi.org\/10.1093\/ibd\/izae231.","DOI":"10.1093\/ibd\/izae231"},{"key":"1050_CR32","doi-asserted-by":"publisher","unstructured":"Porth R, Deyhim T, Zullow S, et al. Proactive therapeutic drug monitoring is associated with increased drug persistence in patients with inflammatory bowel disease treated with intravenous vedolizumab. Inflamm Bowel Dis. 2024;izae140. https:\/\/doi.org\/10.1093\/ibd\/izae140","DOI":"10.1093\/ibd\/izae140"},{"issue":"7","key":"1050_CR33","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1007\/s40261-023-01280-9","volume":"43","author":"P Herranz-Pinto","year":"2023","unstructured":"Herranz-Pinto P, Alonso-Pacheco ML, Feltes-Ochoa R, et al. Real-world performance of a new strategy for off-label use of guselkumab in moderate to severe psoriasis: super-responder patients as the epitome of efficacy and optimisation. Clin Drug Investig. 2023;43(7):517\u201327. https:\/\/doi.org\/10.1007\/s40261-023-01280-9.","journal-title":"Clin Drug Investig"},{"key":"1050_CR34","doi-asserted-by":"publisher","unstructured":"Ruiz-Villaverde R, Vasquez-Chinchay F, Rodriguez-Fernandez-Freire L, J CA-H, P\u00e9rez-Gil A, Gal\u00e1n-Guti\u00e9rrez M. Super-responders in moderate-severe psoriasis under guselkumab treatment: myths, realities and future perspectives. Life (Basel). 2022;12(9). https:\/\/doi.org\/10.3390\/life12091412.","DOI":"10.3390\/life12091412"},{"issue":"3","key":"1050_CR35","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1016\/j.cgh.2019.05.029","volume":"18","author":"E Dreesen","year":"2020","unstructured":"Dreesen E, Baert F, Laharie D, et al. Monitoring a combination of calprotectin and infliximab identifies patients with mucosal healing of Crohn\u2019s disease. Clin Gastroenterol Hepatol. 2020;18(3):637-646.e11. https:\/\/doi.org\/10.1016\/j.cgh.2019.05.029.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"4","key":"1050_CR36","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1097\/mpg.0000000000002833","volume":"71","author":"MA Aardoom","year":"2020","unstructured":"Aardoom MA, Jongsma MME, de Vries A, Wolthoorn J, de Ridder L, Escher JC. vedolizumab trough levels in children with anti-tumor necrosis factor refractory inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2020;71(4):501\u20137. https:\/\/doi.org\/10.1097\/mpg.0000000000002833.","journal-title":"J Pediatr Gastroenterol Nutr."},{"issue":"1","key":"1050_CR37","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1007\/s00431-023-05255-y","volume":"183","author":"M Hemming-Harlo","year":"2024","unstructured":"Hemming-Harlo M, Merras-Salmio L, Nikkonen A, Kolho KL. Drug levels of VEDOLIZUMAB in patients with pediatric-onset inflammatory bowel disease in a real-life setting. Eur J Pediatr. 2024;183(1):313\u201322. https:\/\/doi.org\/10.1007\/s00431-023-05255-y.","journal-title":"Eur J Pediatr"},{"issue":"3","key":"1050_CR38","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1111\/apt.16937","volume":"56","author":"N VandeCasteele","year":"2022","unstructured":"VandeCasteele N, Sandborn WJ, Feagan BG, et al. Real-world multicentre observational study including population pharmacokinetic modelling to evaluate the exposure-response relationship of vedolizumab in inflammatory bowel disease: ERELATE Study. Aliment Pharmacol Ther. 2022;56(3):463\u201376. https:\/\/doi.org\/10.1111\/apt.16937.","journal-title":"Aliment Pharmacol Ther"},{"key":"1050_CR39","doi-asserted-by":"publisher","unstructured":"Sattler L, Hanauer SB, Malter L. Immunomodulatory agents for treatment of patients with inflammatory bowel disease (Review safety of anti-TNF, anti-integrin, Anti IL-12\/23, JAK inhibition, sphingosine 1-Phosphate receptor modulator, azathioprine \/ 6-MP and Methotrexate). Curr. Gastroenterol. Rep. 2021;23(12):30. https:\/\/doi.org\/10.1007\/s11894-021-00829-y.","DOI":"10.1007\/s11894-021-00829-y"},{"key":"1050_CR40","doi-asserted-by":"publisher","unstructured":"Cheifetz AS, Abreu MT, Afif W, et al. A comprehensive literature review and expert consensus statement on therapeutic drug monitoring of biologics in inflammatory bowel disease. Am J Gastroenterol. 2021;116(10):2014-2025. https:\/\/doi.org\/10.14309\/ajg.0000000000001396.","DOI":"10.14309\/ajg.0000000000001396"},{"issue":"Suppl 3","key":"1050_CR41","doi-asserted-by":"publisher","first-page":"s1","DOI":"10.1136\/gutjnl-2019-318484","volume":"68","author":"CA Lamb","year":"2019","unstructured":"Lamb CA, Kennedy NA, Raine T, et al. British society of gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. Gut. 2019;68(Suppl 3):s1\u2013106. https:\/\/doi.org\/10.1136\/gutjnl-2019-318484.","journal-title":"Gut"},{"issue":"9","key":"1050_CR42","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1016\/j.cgh.2019.03.037","volume":"17","author":"K Papamichael","year":"2019","unstructured":"Papamichael K, Cheifetz AS, Melmed GY, et al. Appropriate therapeutic drug monitoring of biologic agents for patients with inflammatory bowel diseases. Clin Gastroenterol Hepatol. 2019;17(9):1655-1668.e3. https:\/\/doi.org\/10.1016\/j.cgh.2019.03.037.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"11\u201312","key":"1050_CR43","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1111\/apt.14368","volume":"46","author":"N Mitrev","year":"2017","unstructured":"Mitrev N, VandeCasteele N, Seow CH, et al. Review article: consensus statements on therapeutic drug monitoring of anti-tumour necrosis factor therapy in inflammatory bowel diseases. Aliment Pharmacol Ther. 2017;46(11\u201312):1037\u201353. https:\/\/doi.org\/10.1111\/apt.14368.","journal-title":"Aliment Pharmacol Ther"},{"key":"1050_CR44","unstructured":"National Institute for Health and Care Excellence (NICE). NICE process and methods guides. Diagnostics Assessment Programme Manual. National Institute for Health and Care Excellence (NICE); 2011."},{"key":"1050_CR45","doi-asserted-by":"publisher","unstructured":"Philipson T, MacEwan JP. The importance of model inputs and assumptions in conducting health technology assessments of novel drugs. J. Med. Econ. 2017;20(10):1107-1109. https:\/\/doi.org\/10.1080\/13696998.2017.1359182.","DOI":"10.1080\/13696998.2017.1359182"},{"key":"1050_CR46","doi-asserted-by":"publisher","unstructured":"Mukherjee K, Gunsoy NB, Kristy RM, et al. Handling missing data in health economics and outcomes research (HEOR): a systematic review and practical recommendations. PharmacoEconomics. 2023;41(12):1589-1601. https:\/\/doi.org\/10.1007\/s40273-023-01297-0","DOI":"10.1007\/s40273-023-01297-0"},{"issue":"1","key":"1050_CR47","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s00535-016-1266-1","volume":"52","author":"L Martelli","year":"2017","unstructured":"Martelli L, Olivera P, Roblin X, Attar A, Peyrin-Biroulet L. Cost-effectiveness of drug monitoring of anti-TNF therapy in inflammatory bowel disease and rheumatoid arthritis: a systematic review. J Gastroenterol. 2017;52(1):19\u201325. https:\/\/doi.org\/10.1007\/s00535-016-1266-1.","journal-title":"J Gastroenterol."},{"issue":"8","key":"1050_CR48","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta25080","volume":"25","author":"IA Tikhonova","year":"2021","unstructured":"Tikhonova IA, Yang H, Bello S, et al. Enzyme-linked immunosorbent assays for monitoring TNF-alpha inhibitors and antibody levels in people with rheumatoid arthritis: a systematic review and economic evaluation. Health Technol Assess. 2021;25(8):1\u2013248. https:\/\/doi.org\/10.3310\/hta25080.","journal-title":"Health Technol Assess"},{"key":"1050_CR49","doi-asserted-by":"publisher","unstructured":"Krieckaert C, Hernandez-Breijo B, Gehin JE, et al. Therapeutic drug monitoring of biopharmaceuticals in inflammatory rheumatic and musculoskeletal disease: a systematic literature review informing EULAR points to consider. RMD Open. 2022;8(2). https:\/\/doi.org\/10.1136\/rmdopen-2022-002216.","DOI":"10.1136\/rmdopen-2022-002216"},{"key":"1050_CR50","doi-asserted-by":"publisher","first-page":"152302","DOI":"10.1016\/j.semarthrit.2023.152302","volume":"63","author":"W Dong","year":"2023","unstructured":"Dong W, Hu X, Wu C, et al. Efficacy, safety, and cost-effectiveness of therapeutic drug monitoring (TDM) for TNF inhibitor therapy in rheumatic disease: A systematic review and meta-analysis. Semin Arthritis Rheum. 2023;63:152302. https:\/\/doi.org\/10.1016\/j.semarthrit.2023.152302.","journal-title":"Semin Arthritis Rheum"},{"issue":"2","key":"1050_CR51","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1136\/annrheumdis-2013-204101","volume":"74","author":"CL Krieckaert","year":"2015","unstructured":"Krieckaert CL, Nair SC, Nurmohamed MT, et al. Personalised treatment using serum drug levels of adalimumab in patients with rheumatoid arthritis: an evaluation of costs and effects. Ann Rheum Dis. 2015;74(2):361\u20138. https:\/\/doi.org\/10.1136\/annrheumdis-2013-204101.","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"1050_CR52","doi-asserted-by":"publisher","first-page":"2397","DOI":"10.1111\/jgh.15373","volume":"36","author":"J Yao","year":"2021","unstructured":"Yao J, Jiang X, You JHS. Proactive therapeutic drug monitoring of adalimumab for pediatric Crohn\u2019s disease patients: a cost-effectiveness analysis. J Gastroenterol Hepatol. 2021;36(9):2397\u2013407. https:\/\/doi.org\/10.1111\/jgh.15373.","journal-title":"J Gastroenterol Hepatol"},{"key":"1050_CR53","doi-asserted-by":"publisher","unstructured":"Feuerstein JD, Nguyen GC, Kupfer SS, et al. American gastroenterological association institute guideline on therapeutic drug monitoring in inflammatory bowel disease. Gastroenterology. 2017;153(3):827-834. https:\/\/doi.org\/10.1053\/j.gastro.2017.07.032","DOI":"10.1053\/j.gastro.2017.07.032"},{"key":"1050_CR54","doi-asserted-by":"publisher","first-page":"864888","DOI":"10.3389\/fmed.2022.864888","volume":"9","author":"CA Martins","year":"2022","unstructured":"Martins CA, Garcia KS, Queiroz NSF. Multi-utility of therapeutic drug monitoring in inflammatory bowel diseases. Front Med (Lausanne). 2022;9:864888. https:\/\/doi.org\/10.3389\/fmed.2022.864888.","journal-title":"Front Med (Lausanne)"},{"key":"1050_CR55","unstructured":"National Institute for Health and Care Excellence (NICE). Therapeutic monitoring of TNF-alpha inhibitors in rheumatoid arthritis. Diagnostics guidance. 2019."},{"key":"1050_CR56","doi-asserted-by":"publisher","unstructured":"Gavan SP, Jani M, Bluett J, Payne K, Barton A. Therapeutic monitoring of TNF inhibitors for rheumatoid arthritis: evidence required following NICE\u2019s recommendations. Rheumatol Adv Pract. 2020;4(2):rkaa023. https:\/\/doi.org\/10.1093\/rap\/rkaa023.","DOI":"10.1093\/rap\/rkaa023"},{"issue":"1","key":"1050_CR57","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1136\/annrheumdis-2022-222155","volume":"82","author":"CLM Krieckaert","year":"2023","unstructured":"Krieckaert CLM, van Tubergen A, Gehin JE, et al. EULAR points to consider for therapeutic drug monitoring of biopharmaceuticals in inflammatory rheumatic and musculoskeletal diseases. Ann Rheum Dis. 2023;82(1):65. https:\/\/doi.org\/10.1136\/annrheumdis-2022-222155.","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"1050_CR58","doi-asserted-by":"publisher","first-page":"2131","DOI":"10.1093\/rheumatology\/kew292","volume":"55","author":"M Jani","year":"2016","unstructured":"Jani M, Gavan S, Chinoy H, et al. A microcosting study of immunogenicity and tumour necrosis factor alpha inhibitor drug level tests for therapeutic drug monitoring in clinical practice. Rheumatology (Oxford). 2016;55(12):2131\u20137. https:\/\/doi.org\/10.1093\/rheumatology\/kew292.","journal-title":"Rheumatology (Oxford)."},{"key":"1050_CR59","doi-asserted-by":"crossref","unstructured":"Cutler DM, Zeckhauser RJ. Adverse Selection in Health Insurance. In: Frontiers in health policy research, Volume 1. MIT Press; 1998.","DOI":"10.2202\/1558-9544.1056"},{"key":"1050_CR60","unstructured":"Rowland C. \u2018There\u2019s a lot of screaming into the void\u2019: toddler\u2019s parents battle for coverage of $2.1 million gene therapy. The Washington Post. 2019. https:\/\/www.washingtonpost.com\/business\/economy\/theres-a-lot-of-screaming-into-the-void-toddlers-parents-battle-for-coverage-of-21-million-gene-therapy\/2019\/07\/10\/76d834bc-9da5-11e9-9ed4-c9089972ad5a_story.html."},{"key":"1050_CR61","unstructured":"WG4: cost-effectiveness assessment, acceptability and implementation. 2024. https:\/\/enotta.eu\/working-groups\/wg4-cost-effectiveness\/."},{"issue":"1","key":"1050_CR62","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1007\/s40271-021-00533-z","volume":"15","author":"CM Vass","year":"2022","unstructured":"Vass CM, Barton A, Payne K. Towards personalising the use of biologics in rheumatoid arthritis: a discrete choice experiment. Patient. 2022;15(1):109\u201319. https:\/\/doi.org\/10.1007\/s40271-021-00533-z.","journal-title":"Patient."},{"key":"1050_CR63","doi-asserted-by":"publisher","unstructured":"Gavan SP, Payne K, Barton A. Overcoming provider barriers to therapeutic drug monitoring of tumour necrosis factor inhibitors for rheumatoid arthritis: a qualitative analysis. Rheumatol Adv Pract. 2024;8(2):rkae030. https:\/\/doi.org\/10.1093\/rap\/rkae030","DOI":"10.1093\/rap\/rkae030"},{"issue":"1","key":"1050_CR64","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1080\/19420862.2018.1532766","volume":"11","author":"C Metcalfe","year":"2019","unstructured":"Metcalfe C, Dougall T, Bird C, et al. The first World Health Organization international standard for infliximab products: a step towards maintaining harmonized biological activity. MAbs. 2019;11(1):13\u201325. https:\/\/doi.org\/10.1080\/19420862.2018.1532766.","journal-title":"MAbs."},{"key":"1050_CR65","doi-asserted-by":"publisher","first-page":"636420","DOI":"10.3389\/fimmu.2021.636420","volume":"12","author":"M Wadhwa","year":"2021","unstructured":"Wadhwa M, Bird C, Atkinson E, Cludts I, Rigsby P. The first WHO International Standard for Adalimumab: dual role in bioactivity and therapeutic drug monitoring. Front Immunol. 2021;12:636420. https:\/\/doi.org\/10.3389\/fimmu.2021.636420.","journal-title":"Front Immunol"},{"key":"1050_CR66","doi-asserted-by":"publisher","unstructured":"l'Ami MJ, Krieckaert CL, Nurmohamed MT, et al. Successful reduction of overexposure in patients with rheumatoid arthritis with high serum adalimumab concentrations: an open-label, non-inferiority, randomised clinical trial. Ann Rheum Dis. 2018;77(4):484-487. https:\/\/doi.org\/10.1136\/annrheumdis-2017-211781.","DOI":"10.1136\/annrheumdis-2017-211781"},{"issue":"Suppl 1","key":"1050_CR67","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1136\/annrheumdis-2024-eular.5266","volume":"83","author":"S Atiqi","year":"2024","unstructured":"Atiqi S, Wientjes MHM, Leeuw M, et al. POS0017 successful therapeutic drug monitoring based adalimumab dose reduction in rheumatoid arthritis patient with low disease activity (Addora-low): a single blind, non-inferiority, randomized clinical trial. Ann Rheum Dis. 2024;83(Suppl 1):450\u2013450. https:\/\/doi.org\/10.1136\/annrheumdis-2024-eular.5266.","journal-title":"Ann Rheum Dis"},{"issue":"15","key":"1050_CR68","doi-asserted-by":"publisher","first-page":"e1452","DOI":"10.1212\/wnl.0000000000008243","volume":"93","author":"LZ Ryerson","year":"2019","unstructured":"Ryerson LZ, Foley J, Chang I, et al. Risk of natalizumab-associated PML in patients with MS is reduced with extended interval dosing. Neurology. 2019;93(15):e1452\u201362. https:\/\/doi.org\/10.1212\/wnl.0000000000008243.","journal-title":"Neurology"},{"issue":"6","key":"1050_CR69","doi-asserted-by":"publisher","first-page":"e745","DOI":"10.1212\/wnl.0000000000009995","volume":"95","author":"ZLE van Kempen","year":"2020","unstructured":"van Kempen ZLE, Hoogervorst ELJ, Wattjes MP, et al. Personalized extended interval dosing of natalizumab in MS: a prospective multicenter trial. Neurology. 2020;95(6):e745\u201354. https:\/\/doi.org\/10.1212\/wnl.0000000000009995.","journal-title":"Neurology"},{"issue":"6","key":"1050_CR70","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1080\/14737159.2020.1757436","volume":"20","author":"P Keeling","year":"2020","unstructured":"Keeling P, Clark J, Finucane S. Challenges in the clinical implementation of precision medicine companion diagnostics. Expert Rev Mol Diagn. 2020;20(6):593\u20139. https:\/\/doi.org\/10.1080\/14737159.2020.1757436.","journal-title":"Expert Rev Mol Diagn"},{"key":"1050_CR71","unstructured":"Staton T. Bristol-Myers\u2019 Opdivo far outpaced Merck\u2019s Keytruda again in Q2. What gives? Fierce Pharma. 2016. https:\/\/www.fiercepharma.com\/marketing\/bristol-myers-opdivo-far-outpaced-merck-s-keytruda-again-q2-what-gives."},{"issue":"4","key":"1050_CR72","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1002\/jcph.2384","volume":"64","author":"AL Nguyen","year":"2024","unstructured":"Nguyen AL, Gibson PR, Upton RN, Mould DR, Sparrow MP. Application of a precision-dosing model to a real-world cohort of patients on infliximab maintenance therapy: drug usage and cost analysis. J Clin Pharmacol. 2024;64(4):399\u2013409. https:\/\/doi.org\/10.1002\/jcph.2384.","journal-title":"J Clin Pharmacol."},{"issue":"1","key":"1050_CR73","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1208\/s12248-016-9994-y","volume":"19","author":"MC Dubinsky","year":"2017","unstructured":"Dubinsky MC, Phan BL, Singh N, Rabizadeh S, Mould DR. Pharmacokinetic dashboard-recommended dosing is different than standard of care dosing in infliximab-treated pediatric IBD patients. AAPS J. 2017;19(1):215\u201322. https:\/\/doi.org\/10.1208\/s12248-016-9994-y.","journal-title":"AAPS J"},{"issue":"4","key":"1050_CR74","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1097\/ftd.0000000000000404","volume":"39","author":"K Bloem","year":"2017","unstructured":"Bloem K, Hern\u00e1ndez-Breijo B, Mart\u00ednez-Feito A, Rispens T. Immunogenicity of therapeutic antibodies: monitoring antidrug antibodies in a clinical context. Ther Drug Monit. 2017;39(4):327\u201332. https:\/\/doi.org\/10.1097\/ftd.0000000000000404.","journal-title":"Ther Drug Monit"},{"key":"1050_CR75","unstructured":"ADVATE. Antihemophilic factor (Recombinant), plasma\/albumin-free method. Prescribing Information Accessed 2024, https:\/\/www.fda.gov\/media\/70008\/download?attachment."},{"key":"1050_CR76","unstructured":"ADYNOVATE. Antihemophilic factor, recombinant, PEGylated. Prescribing Information. 2024. https:\/\/www.fda.gov\/media\/94470\/download."}],"container-title":["The AAPS Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12248-025-01050-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1208\/s12248-025-01050-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12248-025-01050-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,24]],"date-time":"2025-03-24T23:40:46Z","timestamp":1742859646000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1208\/s12248-025-01050-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,14]]},"references-count":76,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,3]]}},"alternative-id":["1050"],"URL":"https:\/\/doi.org\/10.1208\/s12248-025-01050-9","relation":{},"ISSN":["1550-7416"],"issn-type":[{"value":"1550-7416","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,14]]},"assertion":[{"value":"2 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The views expressed in this article are those of the authors and do not necessarily reflect the official views of the FDA.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclaimer"}},{"value":"ASC has received consulting fees from Abbvie, Aegirbio (SAB), Artizan (SAB), Prometheus (SAB), Fzata, Adiso, BMS, Clario, Food is Good, Fresenius Kabi, Janssen, Lilly, Pfizer, Procise, Spherix, Samsung; and speaking fees (non-branded) from Abbvie, BMS, Janssen. MRT has received consulting fees from Boehringer Ingelheim, Janssen Pharmaceuticals, Merck, Pfizer, Roche Pharmaceuticals, UniQure. DRM is president of Projections Research Inc, a consulting company working with the pharmaceutical industry. The remaining authors report no conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}],"article-number":"62"}}